Expression And Clinical Significance Study Of Serum GP73in HBV-related Chronic Liver Disease

Objective:To investigate the level of serum Golgi Protein73(GP73)and explore the clinical significance of serum GP73in different types ofchronic liver diseases caused by hepatitis B virus(HBV) infection.Methods:222serum specimans，including17cases of HBV car-riers,70cases of chronic hepatitis B（CHB),57cases of liver cirrh-osis(LC),33cases of hepatocellular carcinoma（HCC) and45cases of healthy controls were collected.The levels of serum GP73were measured by ELISA, and ALB,DB,TB,ALT,AST,ALP,GGT by bioche-mical analyzer.Using electrochemiluminescence for the detection of AFP and chemiluminometry method for the HA, LN, PIIINP, CIV. Real-time fluorescence quantitative PCR detection of HBV DNA.PT, PTA were measuredby the fully automatic blood coagulation analyzer.SPSS17.0statistical software for statistical analysis.The correlation be-tween GP73and otherserum makers was analyzed with Spearman correlation analysis.Results: The levels of serum GP73in HBV carriers and healthy controls were563.803±11.197ng/L,558.853±5.883ng/L.No significant dif ference can be found between them (P=0.646).The expression leve-ls of GP73from high to low were HCC (1561.741±11.912ng/L),CHB (700.756±19.337ng/L),LC (675.294±32.761ng/L),healthy controls (558.853±5.883ng/L) and HBV carriers (563.803±11.197ng/L) group (P<0.01).Serum GP73in moderate CHB group(716.178±19.127ng/L) and severe CHB group(704.632±15.389ng/L) were higher than that in the mild CHBone (688.751±10.114ng/L)(both P<0.01), difference was not obviousbetween the first two groups (P=0.104).There was positi-ve correlation(r=0.438,P<0.001) between HBV DNA and GP73in CHB.Serum GP73level in patients with compensated cirrhosis (661.738±30.511ng/L) was higher than that in the decompensatory ones(702.406±16.178ng/L),(P=0.02).No significant difference of GP73in AFP negative HCC patients (1562.550±13.964ng/L) and AFP positive HCC(1561.070±10.269ng/L)(P=0.727).Spearman correlation analysis showed that GP73had negative correlations with ALB (r=-0.964, P<0.01) in HBV carriers; negative with ALB、PTA (r=-0.816,-0.430,P <0.01) and positive with DB,TB,ALT,AST,ALP,GGT,PT, HA,PIIINP, CIV,lgDNA(r=0.609,0.633,0.330,0.373,0.321,0.441,0.468,0.423,0.278,0.274,0.438,P<0.05) in CHB group；positive with ALP, GGT,PT,HA,CIV(r=0.368,0.382,0.382,0.330,0.383,P <0.05) in LC group； negative withALB (r=-0.858, P <0.01), andpositive with DB,TB,ALT,AST,AFP, lgDNA (r=0.936,0.945,0.693,0.456,0.250,0.434, P <0.05) in HCC. Conclusion: First to investigate the serum GP73expression levels inCHB, LC, HCC, HBV carriers caused by the chronic HBV infection andpoint out the differences among each subgroups.High-level expression ofserum GP73in CHB, LC group indicated the survival function of the livercells and severe structural damage or fibrosis.High levels of GP73inchronic HBV infection patients were related to the increasing HBV DNAload,led to liver damage with the exacerbation of cellularimmunology.Serum GP73expressed at a high level in HCC patients can beused as a serum marker of HCC especially when AFP is normal.